Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + temozolomide + anlotinib
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the anti-angiogenic monoclonal antibody bevacizumab, the oral alkylating chemotherapy agent temozolomide, and the multi-target tyrosine kinase inhibitor (TKI) anlotinib. Bevacizumab works by binding to and neutralizing vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis. Temozolomide is a prodrug that delivers a methyl group to DNA, primarily at the O6 and N7 positions of guanine, leading to DNA damage and apoptosis in rapidly dividing tumor cells. Anlotinib further suppresses tumor growth and vascularization by inhibiting multiple receptor tyrosine kinases, including VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. This triple regimen is primarily investigated for the treatment of glioblastoma, particularly in recurrent or refractory cases, to overcome resistance to standard therapies. The Affiliated Cancer Hospital of Shandong First Medical University has been a key institution in evaluating this combination in clinical trials.
- Brand names
- Focus V
- Other names
- Bevacizumab plus Temozolomide plus Anlotinib
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNAPDGFRA (Platelet-derived growth factor receptor alpha)VEGFA (Vascular endothelial growth factor A)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on bevacizumab + temozolomide + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + temozolomide + anlotinib.